Inovio Pharmaceuticals Company Profile (NASDAQ:INO)

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Inovio Pharmaceuticals's stock reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) issued its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.31) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.31). The business had revenue of $10.40 million for the quarter, compared to the consensus estimate of $5.83 million. Inovio Pharmaceuticals had a negative return on equity of 65.97% and a negative net margin of 235.91%. The firm's quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.11) EPS. View Inovio Pharmaceuticals' Earnings History.

9 brokerages have issued twelve-month price targets for Inovio Pharmaceuticals' shares. Their predictions range from $11.00 to $40.00. On average, they expect Inovio Pharmaceuticals' share price to reach $22.11 in the next year. View Analyst Ratings for Inovio Pharmaceuticals.

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:

• 1. Maxim Group analysts commented, "Inovio announced a collaboration with Roche (RHHBY – $34.10 – NR) to evaluate their DNA-based immunotherapies INO-5401 (multiple cancer antigens) and INO-9012 (IL-12 immune stimulator) with Tecentriq (PD-L1 checkpoint) in advanced bladder cancer." (6/1/2017)
• 2. According to Zacks Investment Research, "Inovio reported narrower than expected loss in first quarter of 2017, with revenue beating estimates. Inovio is a development-stage biopharmaceutical company is focused on the development of treatments targeting various forms of cancer and infectious diseases. We are pleased with the company’s collaborations with other firms for pipeline development. Shares of Inovio have outperformed the Medical-Biomedical/Genetics industry so far this year. However, Inovio suffered a setback with the FDA placing clinical hold on the proposed phase III program on its lead pipeline candidate, VGX-3100 in Oct 2016. Though in Apr 2017, Inovio submitted a complete response to the FDA for the initiation of the study, FDA decision is still pending. Moreover, Inovio’s over-dependence on government grants and contracts for the development of its candidates is also concerning." (5/15/2017)

Some companies that are related to Inovio Pharmaceuticals include Medpace Holdings (MEDP), Genomic Health (GHDX), Genus plc (GNS), Esperion Therapeutics (ESPR), Albany Molecular Research (AMRI), Heron Therapeutics (HRTX), Cellectis SA (CLLS), TG Therapeutics (TGTX), Editas Medicine (EDIT), Enanta Pharmaceuticals (ENTA), Mesoblast Limited (MESO), CRISPR THERAPTC (CRSP), Spectrum Pharmaceuticals (SPPI), WAVE Life Sciences (WVE), ANI Pharmaceuticals (ANIP), ImmunoGen (IMGN), AC Immune SA (ACIU) and Arena Pharmaceuticals (ARNA).

Inovio Pharmaceuticals' management team includes the folowing people:

• Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director
• Peter D. Kies, Chief Financial Officer
• Niranjan Y. Sardesai Ph.D., Chief Operating Officer
• Mark L. Bagarazzi M.D., Chief Medical Officer
• Avtar S. Dhillon M.D., Non-Executive Chairman of the Board
• George W. Bickerstaff III, Director
• David B. Weiner, Director
• Simon X. Benito, Independent Director
• Angel Cabrera Ph.D., Independent Director

Inovio Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.18%), State Street Corp (3.37%), Morgan Stanley (0.89%), Geode Capital Management LLC (0.76%), Bank of New York Mellon Corp (0.46%) and Schwab Charles Investment Management Inc. (0.41%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.

Inovio Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Group AG, State Street Corp, Goldman Sachs Group Inc., Alliancebernstein L.P., TIAA CREF Investment Management LLC, ProShare Advisors LLC and Bellevue Group AG. Company insiders that have sold Inovio Pharmaceuticals stock in the last year include David B Weiner, Jong Joseph Kim and Niranjan Sardesai. View Insider Buying and Selling for Inovio Pharmaceuticals.

Inovio Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Credit Suisse AG, Geode Capital Management LLC, Wells Fargo & Company MN, Vident Investment Advisory LLC, Schwab Charles Investment Management Inc., Bank of New York Mellon Corp and Metropolitan Life Insurance Co. NY. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Morton Collins, Niranjan Sardesai and Simon X Benito. View Insider Buying and Selling for Inovio Pharmaceuticals.

Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $8.20.